Clinical Trial: Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07581782) titled 'Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)' on May 06.

Brief Summary: Evaluate the benefit of faricimab (4 loading doses + PRN) on best-corrected visual acuity in patients with nAMD. Evaluate the safety and anatomical improvement of faricimab (4 loading doses + PRN) in patients with nAMD.

Study Start Date: June 01

Study Type: OBSERVATIONAL

Condition: Neovascular Age-related Macular Degeneration(nAMD)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Sun Yat-sen University

Information provided by (Responsible Party): Jin Chen-jin, Sun Yat-sen U...